Beta Drugs Balance Sheet Health

Financial Health criteria checks 6/6

Beta Drugs has a total shareholder equity of ₹1.4B and total debt of ₹154.2M, which brings its debt-to-equity ratio to 10.9%. Its total assets and total liabilities are ₹2.4B and ₹952.9M respectively. Beta Drugs's EBIT is ₹484.7M making its interest coverage ratio 26.2. It has cash and short-term investments of ₹233.5M.

Key information

10.9%

Debt to equity ratio

₹154.24m

Debt

Interest coverage ratio26.2x
Cash₹233.54m
Equity₹1.42b
Total liabilities₹952.89m
Total assets₹2.37b

Recent financial health updates

Recent updates

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Financial Position Analysis

Short Term Liabilities: BETA's short term assets (₹1.6B) exceed its short term liabilities (₹832.8M).

Long Term Liabilities: BETA's short term assets (₹1.6B) exceed its long term liabilities (₹120.1M).


Debt to Equity History and Analysis

Debt Level: BETA has more cash than its total debt.

Reducing Debt: BETA's debt to equity ratio has reduced from 38.1% to 10.9% over the past 5 years.

Debt Coverage: BETA's debt is well covered by operating cash flow (179.6%).

Interest Coverage: BETA's interest payments on its debt are well covered by EBIT (26.2x coverage).


Balance Sheet


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.